Clinical Research Directory
Browse clinical research sites, groups, and studies.
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Sponsor: Vir Biotechnology, Inc.
Summary
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
Official title: A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
95
Start Date
2022-09-17
Completion Date
2029-08
Last Updated
2025-10-14
Healthy Volunteers
No
Conditions
Interventions
VIR-2218
VIR-2218 given by subcutaneous injection
VIR-3434
VIR-3434 given by subcutaneous injection
NRTI
NRTI given orally.
Locations (20)
Investigative Site
Sofia, Bulgaria
Investigative Site
Sofia, Bulgaria
Investigative Site
Stara Zagora, Bulgaria
Investigative Site
Clichy, France
Investigative Site
Pessac, France
Investigative Site
Rennes, France
Investigative Site
Toulouse, France
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Tübingen, Germany
Investigative Site
Milan, Italy
Investigative Site
Pisa, Italy
Investigative Site
Chisinau, Moldova
Investigative Site
Rotterdam, Netherlands
Investigative Site
Auckland, New Zealand
Investigative Site
Bucharest, Romania
Investigative Site
Birmingham, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom